TABLE 2.
Mean GP5 Scores by Maximum AE Grade at Day 28 of Cycle 2
| Maximum AE Grade | No. | Mean GP5 | SD | ES |
|---|---|---|---|---|
| COMPARZ (N5640) | ||||
| 0 | 62 | 0.60 | 0.78 | - |
| 1 | 221 | 1.05 | 1.02 | 0.46 |
| 2 | 244 | 1.51 | 1.15 | 0.42 |
| 3–4 | 113 | 1.85 | 1.15 | 0.30 |
| ENESTnd (N5345) | ||||
| 0 | 167 | 0.60 | 0.90 | - |
| 1 | 120 | 0.94 | 0.96 | 0.36 |
| 2–3 | 58 | 1.24 | 1.01 | 0.30 |
Abbreviations: AE, adverse event; COMPARZ, Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma; ENESTnd, Evaluating Nilotinib Efficacy and Safety in Clinical Trials–Newly Diagnosed Patients; ES, effect size (mean difference between adjacent groups/pooled standard deviation); GP5, Functional Assessment of Cancer Therapy-General version (FACT-G) single item (“I am bothered by side effects of treatment”); SD, standard deviation.